Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11840-11850

  Allen, Cory ^a   Vongpunsawad, Sompong ^a   Nakamura, Takafumi ^a   James, C David ^a   Schroeder, Mark ^a   Cattaneo, Roberto ^a   Giannini, Caterina ^a   Krempski, James ^a   Peng, Kah Whye ^a   Goble, Jenny M ^a   Uhm, Joon H ^a   Russell, Stephen J ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GREEN FLUORESCENT PROTEIN; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC VIRUS; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROTECTION; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MACROPHAGE; MEASLES VIRUS; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA TRANSLATION; VERO CELL; VIRUS REPLICATION; VIRUS STRAIN; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; DNA PRIMERS; GENES, REPORTER; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; MEASLES; MEASLES VACCINE; MEASLES VIRUS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VERO CELLS; VIRAL PROTEINS;

EID: 33846213523     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1200     Document Type: Article

References (45)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003;63:2462-9.
3. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75:295-305.
4. Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993;67:6025-32.
5. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406:893-7.
6. Hahm B, Arbour N, Naniche D, Homann D, Manchester M, Oldstone MB. Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule. J Virol 2003;77:3505-15.
7. Schneider-Schaulies S, Bieback K, Avota E, Klagge I, ter Meulen V. Regulation of gene expression in lymphocytes and antigen-presenting cells by measles virus: consequences for immunomodulation. J Mol Med 2002;80:73-85.
8. McQuaid S, Cosby SL. An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab Invest 2002;82:403-9.
9. Shusta EV, Zhu C, Boado RJ, Pardridge WM. Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier. J Neuropathol Exp Neurol 2002;61:597-604.
10. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 2004;78:302-3.
11. Nakamura T, Peng KW, Vongpunsawad S, et al. Antibody-targeted cell fusion. Nat Biotechnol 2004;22:331-6.
12. Nakamura T, Peng KW, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005;23:209-14.
13. Hadac EM, Peng KW, Nakamura T, Russell SJ. Reengineering paramyxovirus tropism. Virology 2004;329:217-25.
14. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 1990;87:8602-6.
15. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994;9:2313-20.
16. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57:4130-40.
17. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001;38:177-92.
18. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncol 2005;7:164-76.
19. Lorimer IA, Lavictoire SJ. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J Immunol Methods 2000;237:147-57.
20. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J 1995;14:5773-84.
21. Douglas JT, Miller CR, Kim M, et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 1999;17:470-5.
22. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999;73:9568-75.
23. Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 2000;74:9928-36.
24. Cathomen T, Naim HY, Cattaneo R. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 1998;72:1224-34.
25. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia 1995;15:244-56.
26. Frederick L, Wang XV, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7.
27. Galanis E, Buckner J, Kimmel D, et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 1998;13:717-24.
28. Jungbluth AA, Stockert E, Huang HJ. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003;100:639-44.
29. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63:700-7.
30. Beers R, Chowdhury P, Bigner D, Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expres sing cells produced by antibody phage display. Clin Cancer Res 2000;6:2835-43.
31. Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol 2002;23:61-9.
32. Griffin DE. Meales Virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia (PA): Lippincott Williams & Wilkins; 2001. p. 1402-42.
33. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26.
34. Hasegawa K, Nakamura T, Marks JD, Russell SJ, Peng KW. Effect of ligand binding affinity and receptor density in relation to biology of retargeted viruses [abstract 957]. Mol Ther 2006;13:S369.
35. Katze MG, He Y, Gale M, Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-87.
36. Bose S, Banerjee AK. Innate immune response against nonsegmented negative strand RNA viruses. J Interferon Cytokine Res 2003;23:401-12.
37. Takeuchi K, Kadota SI, Takeda M, Miyajima N, Nagata K. Measles virus V protein blocks interferon (IFN)-α/β but not IFN-γ signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett 2003;545:177-82.
38. Yokota S, Saito H, Kubota T, Yokosawa N, Amano K, Fujii N. Measles virus suppresses interferon-α signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-α receptor complex. Virology 2003;306:135-46.
39. Okada H, Sato TA, Katayama A, et al. Comparative analysis of bost responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch Virol 2001;146:859-74.
40. Galanis E, Hartmann LC, Cliby W, et al. Phase 1 trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients [abstract 5028]. J Clin Oncol 2006;24:262s.
41. Holland EC. A mouse model for glioma: biology, pathology, and therapeutic opportunities. Toxicol Pathol 2000;28:171-7.
42. Humphrey PA, Wong AJ, Vogelstein B, et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 1988;48:2231-8.
43. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003;63:6463-8.
44. Meadows GG, Abdallah RM, Starkey JR, Aslakson CJ. Response of natural killer cells from dietary tyrosine- and phenylalanine-restricted mice to biological response modifiers. Cancer Immunol Immunother 1988;26:67-73.
45. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203.